Eli Lilly & CO Form 4 insider transactions

Eli Lilly & Co. Director Ralph Alvarez acquired 11.062 shares of common stock by deferring cash compensation into stock units under the company's deferral plan.

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported the sale of 15,632 common shares for approximately $17.3 million under a pre-arranged trading plan.

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported the sale of 146,052 shares of common stock for approximately $159 million through pre-planned transactions.

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported the sale of 142,307 shares of common stock for approximately $152 million through pre-arranged trading plans.

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported the sale of 95,766 shares of common stock for over $100 million on November 21, 2025, executed under a Rule 10b5-1 trading plan.

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported the sale of 37,148 shares of common stock for approximately $39 million through pre-arranged Rule 10b5-1 plans.

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported the sale of 167,526 shares of common stock on November 19, 2025, under a pre-arranged trading plan.

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported the sale of over 60,000 common shares totaling approximately $62 million under a pre-arranged trading plan.

Eli Lilly director Kimberly H. Johnson acquired 215.327 common shares on November 17, 2025 at $1,021.7 each, lifting her direct holdings to 3,264.731 shares.

Eli Lilly & Co. Director Gabrielle Sulzberger acquired additional common stock through a compensation deferral plan, increasing her beneficial ownership.

Eli Lilly Director Jon R. Moeller acquired 233.271 shares of common stock at $1,021.7 per share on November 17, 2025, increasing his direct beneficial ownership to 304.271 shares.

Eli Lilly & Co. Director Juan R. Luciano acquired additional common stock, including shares deferred as compensation, increasing his beneficial ownership.

Eli Lilly & Co. Director William G. Kaelin Jr. acquired 215.327 shares of common stock at $1,021.7 per share under a pre-arranged trading plan.

Eli Lilly & Co. Director Jamere Jackson acquired 215.327 shares of common stock on November 17, 2025, under a Rule 10b5-1 plan.

Eli Lilly & Co. Director Mary Lynne Hedley acquired additional common stock through a deferred compensation plan, increasing her beneficial ownership.

Director J. Erik Fyrwald reported acquisitions of Eli Lilly stock and deferred stock units on Nov. 17, 2025, lifting direct beneficial ownership to 74,988.689 shares.

Eli Lilly & Co. Director Katherine Baicker acquired 215.327 shares of common stock on November 17, 2025, increasing her direct beneficial ownership.

Eli Lilly & Co. Director Ralph Alvarez acquired additional common stock, increasing his direct beneficial ownership to 55,378.773 shares.

Lilly Endowment, a 10% owner of Eli Lilly (LLY), disclosed open-market sales totaling 9,886 shares at ~$1,031, retaining 92.87 million shares.

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported the sale of 178,295 shares of common stock for approximately $183.7 million on November 14, 2025.

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported the sale of 46,606 shares of common stock for approximately $48 million.

Eli Lilly's SVP of Finance and CAO, Donald A. Zakrowski, sold 1,000 shares of common stock for over $1 million as part of a pre-arranged trading plan.

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported the sale of 309,190 shares of common stock for approximately $312.7 million on November 12, 2025, under a pre-arranged trading plan.

Lilly Endowment Inc., a 10% owner and director of Eli Lilly & Co., reported the sale of over 300,000 common shares totaling approximately $297 million under a pre-arranged 10b5-1 plan.

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported selling 16,869 shares of common stock for approximately $16.4 million on November 10, 2025.

Eli Lilly & Co. CEO David A. Ricks reported a disposition of 24,750 common shares on November 10, 2025, through a non-sale transaction.

Eli Lilly & Co. EVP Daniel Skovronsky reported gifting 179 shares of common stock on November 10, 2025, under a Rule 10b5-1 plan.

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported the sale of 40,432 shares of common stock totaling approximately $38.47 million through pre-planned transactions.

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported the sale of 179,392 shares of common stock for approximately $166.6 million on November 5, 2025, as part of a pre-arranged trading plan.

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported the sale of 526 shares of common stock for approximately $910.72 per share.